What does a P2Y12 platelet function assay result of 288 PRU indicate?

P2Y12 of 288 PRU Indicates High On-Treatment Platelet Reactivity (Hyporesponse to Clopidogrel)

A P2Y12 result of 288 PRU indicates high on-treatment platelet reactivity, meaning the patient is a "hyporesponder" or "non-responder" to clopidogrel, placing them at significantly increased risk for thrombotic complications including stent thrombosis. This value falls well above the commonly used threshold of 208-240 PRU that defines inadequate platelet inhibition 1, 2.

What This Number Means

The P2Y12 assay (VerifyNow system) measures platelet reactivity in P2Y12 Reaction Units (PRU):

• Therapeutic range: 60-200 PRU (some use <208-240 PRU as upper limit)
• High platelet reactivity (hyporesponse): PRU ≥208-240
• Your patient's value of 288 PRU: Significantly elevated, indicating poor response to clopidogrel

In the ADAPT-DES study of 8,582 patients, those in the highest PRU quintile (median 317, similar to your patient's 288) had a 2.32-fold increased risk of stent thrombosis compared to the lowest quintile 3. The relationship between increasing PRU and stent thrombosis was monotonic—meaning risk continues to rise as PRU increases.

Clinical Implications & Risk

Your patient with PRU 288 faces:

• Increased risk of stent thrombosis (2-3 fold higher than therapeutic range) 3
• Higher rates of major adverse cardiac events if post-ACS or post-PCI 4
• Inadequate platelet inhibition from current clopidogrel therapy

Recommended Action

Switch to a more potent P2Y12 inhibitor immediately 1, 2:

First-Line Options (in order of preference):

1. Ticagrelor 90 mg twice daily (preferred over clopidogrel in ACS patients) 5

   • Give 180 mg loading dose when switching from clopidogrel 6
   • More consistent platelet inhibition, not affected by genetic polymorphisms
   • Recommended maintenance aspirin dose: 81 mg daily (not higher) 5, 2

2. Prasugrel 10 mg daily (if no contraindications) 5, 2

   • Give 60 mg loading dose
   • Contraindications: Prior stroke/TIA, age ≥75 years (relative), weight <60 kg (use 5 mg dose), active bleeding 2
   • More predictable response than clopidogrel

Alternative if Switching Not Possible:

• Increase clopidogrel to 150 mg daily (less preferred, inconsistent evidence)
• Consider genetic testing for CYP2C19 loss-of-function variants 2

Important Caveats

Routine platelet function testing is NOT recommended by ACC/AHA guidelines 1, 2. However, testing "may be considered" (Class IIb) in high-risk patients where results would alter management 1, 2. Your patient clearly falls into this category since you have the result and it shows high platelet reactivity.

The guidelines are clear: do not routinely test, but if you do test and find high platelet reactivity, switching to alternative agents is reasonable 1, 2.

Context Matters:

• Post-PCI/stent patients: Highest risk, most urgent need to optimize therapy
• ACS patients: Ticagrelor preferred regardless of testing 5
• Stable CAD: Lower urgency but still warrants consideration of therapy change
• Bleeding risk: If high bleeding risk, the decision becomes more nuanced—but PRU 288 suggests thrombotic risk currently outweighs bleeding risk

What NOT to Do

• Do not continue current clopidogrel dose unchanged in high-risk patients (post-stent, post-ACS)
• Do not use PRU-guided dose de-escalation at this high PRU level 6
• Do not delay intervention in patients with recent stent placement or ACS

Follow-Up

If you switch therapy, repeat testing is not routinely necessary but may be considered in 2-4 weeks if clinical concern persists. Ticagrelor and prasugrel produce more predictable platelet inhibition than clopidogrel, so repeat testing is less informative 6.

Ensure DAPT duration of at least 12 months post-stent (drug-eluting stent) or post-ACS 5, 1, 2.